# US 5,710,181 A · Inhibition of nitric oxide formation in inflammatory bowel disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,710,181 A
- Document ID: US5710181A
- Status: Granted
- Kind: A
- Application number: 08/620,833
- Filed: 1996-03-25
- Granted: 1998-01-20
- Earliest claimed: 1991-12-16
- Assignees: Washington University
- Inventors: Joseph R. Williamson; John A. Corbett; Michael L. McDaniel; Ronald G. Tilton
- Web page: https://patentgrep.com/patent/US5710181A

## CPC

- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with inflammatory bowel disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of aminoguanidine.

## Claims

### Claim 1

A method of inhibiting nitric oxide production in a warm blooded mammal afflicted with inflammatory bowel disease, said method comprising administering a nitric oxide inhibitory effective amount of aminoguanidine.

### Claim 2 (depends on 1)

The method according to claim 1 wherein aminoguanidine is administered orally.

### Claim 3 (depends on 2)

The method according to claim 2 wherein aminoguanidine. is administered in a pharmaceutically acceptable formulation.

### Claim 4 (depends on 3)

The method according to claim 3 wherein aminoguanidine is in a sustained release or delayed release formulation.

### Claim 5 (depends on 1)

The method according to claim 1 wherein aminoguanidine is administered intrarectally.

### Claim 6 (depends on 5)

The method according to claim 5 wherein aminoguanidine is administered in a pharmaceutically acceptable formulation.

### Claim 7 (depends on 1)

The method according to claim 1 wherein aminoguanidine is administered parenterally.

### Claim 8 (depends on 7)

The method according to claim 7 wherein aminoguanidine is administered intravenously or subcutaneously.

### Claim 9 (depends on 8)

The method according to claim 8 wherein aminoguanidine is administered in a pharmaceutically acceptable formulation.